Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
During the index procedure one venaseal closure system was used to treat a lesion located in the great saphenous vein 1 and the small saphenous vein.Approximately 5 months post procedure, during an ulcer follow up visit, the patient was noted to have an area of skin breakdown with a purulent discharge in the medial knee where there was an existing and persistent wound at the procedure access site.The wound was swabbed and the culture came back as positive for staph aureus.The patient was prescribed antibiotics.It was stated that the event is related to target limb but not the target vein.The patient has not recovered.
|